Middle Meningeal Artery Embolization (MMAE) has emerged as a promising treatment option, particularly for managing conditions such as chronic subdural hematoma (cSDH). To ensure this technique continues to evolve and become even safer and more effective, the Safety of Middle ARTery Embolization (SMARTE) Survey has been developed.
The survey aims to gather valuable insights regarding experiences with MMAE, including risks and complications observed in clinical practice. This effort seeks to build a comprehensive understanding of the procedure and identify areas for improvement, ultimately benefiting both practitioners and patients.
Objectives of the SMARTE Survey
The primary goal of the SMARTE Survey is to collect data on:
- Real-world applications of MMAE.
- Challenges encountered during procedures.
- Observed risks and complications, whether directly experienced or shared by colleagues.
This information will guide future research and contribute to refining MMAE protocols, ensuring enhanced patient safety and outcomes.
Key Details
- Duration: The survey takes approximately 7–10 minutes to complete.
- Data Privacy: All responses are anonymized to protect the privacy of participants.
The findings from this survey will be instrumental in driving innovation and supporting the development of evidence-based practices for MMAE.
Access to the Survey
Participation is straightforward and accessible through the provided link or QR code.
Collaborative Effort
This initiative is led by the EYMINT Research and Survey Committee, a group of experts with a strong focus on supporting young professionals, trainees, and early-career researchers in advancing neurointervention and neuroradiology..
By contributing to this survey, participants play a vital role in shaping the future of MMAE, ensuring that this procedure continues to offer improved outcomes for cSDH patients.
The SMARTE Survey represents an important step in refining and advancing MMAE, ultimately supporting the broader medical community’s efforts to provide safe, effective, and innovative care.
